Back to Journals » The Application of Clinical Genetics » Volume 5

Clinical and molecular characterization of a patient with a combination of a deletion and a duplication of 22q13 using array CGH

Authors Ochando I, Urbano, Rubio, Rueda

Received 10 July 2012

Accepted for publication 7 August 2012

Published 7 September 2012 Volume 2012:5 Pages 93—96


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Isabel Ochando,1 Antonio Urbano,1 Juana Rubio,2 Joaquín Rueda1,3

1Unidad de Genética, Hospital Clínica Vistahermosa, Alicante, 2Hospital Virgen de la Vega, Murcia, 3Departamento de Histología y Anatomía, Universidad Miguel Hernández, Alicante, Spain

Abstract: Phelan–McDermid syndrome is caused by the loss of terminal regions of different sizes at 22q13. There is a wide range of severity of symptoms in patients with a 22q13 deletion, but these patients usually show neonatal hypotonia, global developmental delay, and dysmorphic traits. We carried out a clinical and molecular characterization of a patient with neonatal hypotonia and dysmorphic features. Array-based comparative genomic hybridization showed an 8.24 Mb terminal deletion associated with a 0.20 Mb duplication. Characterization of patients with Phelan–McDermid syndrome both clinically and at the molecular level allows genotype-phenotype correlations that provide clues to help elucidate the clinical implications.

Keywords: 22q13 deletion, subtelomeric rearrangements, Phelan–McDermid syndrome, genotype–phenotype correlations

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.